Scientific Programme


* Program subject to change

Thursday, 4 April 2019


08:00-16:30

Registration 

08:50-09:00

Welcome and Opening of the Congress
Pia Raanani, Israel

09:00-10:30

Session 1: Myelodysplsatic Syndromes and Acute Myeloid Leukemia – Can We Aim for Cure?
Chairperson: Richard Stone, Dana-Farber Cancer Institute, USA

09:00-09:25

Can Immune Therapy Cure Acute Myeloid Leukemia?
Robert Peter Gale, Imperial College London, UK

09:25-09:50

Optimizing the Use of FLT3 Inhibitors in AML
Nicholas Short,
The University of Texas MD Anderson Cancer Center,
USA

  • Characteristics of FLT3 inhibitors in clinical development
  • Review of efficacy and safety data from FLT3 inhibitor trials
  • Potential strategies to overcome FLT3 inhibitor resistance

09:50-10:15


Effective AML Therapy via Apoptosis Promotion
Richard Stone,
Dana-Farber Cancer Institute, USA
  • Mechanism of action of venetoclax
  • Review of research leading to the approval of venetoclax in AML
  • Additional strategies to promote apoptosis in myeloid malignancies

10:15-10:30

Discussion

10:30-11:00

Coffee Break, Poster Viewing and Exhibition

11:00-12:30

Session 2: Acute Lymphoblastic Leukemia – From Cure in Childhood Towards Adulthood
Chairperson: Robin Foa, Sapienza University of Rome, Italy

11:00-11:25

Individualized treatment of adult ALL: Chances and Pitfalls
Nicola Gökbuget,
Universitätsklinikum Frankfurt, Germany

11:25-11:50

Advancements in The Management of Acute Lymphoblastic Leukemia
Robin Foa, 
Sapienza University of Rome, Italy

11:50-12:15

Next Generation Treatment Of ALL:  Incorporation of New Agents into Frontline Therapy for All!
Wendy Stock,
The University of Chicago Medicine, USA

  • Current outcomes of adolescent and young adults (AYA) and older adults
  • Challenges with current strategies, particularly for high-risk subsets
  • Strategies for improving outcomes by incorporation of new agents into frontline therapy

12:15-12:30

Discussion 

12:30-13:30

Lunch Break, Poster Viewing and Exhibition

13:30-15:00

Session 3: Myeloproliferative Neoplasms and Chronic Myeloid Leukemia- From Gene to Cure
Chairperson: Radek Skoda, University Hospital Basel, Switzerland

13:30-13:55

CML 2019 - Towards an Age Adjusted Personalized Approach
Pia Raanani, Israel

  • Personalized choice of first line treatment in CML in 2019
  • AYA and CML – perspectives and challenges
  • Elderly patients with CML – cardiovascular risks and choice of treatment

13:55-14:20

Challenges in Pediatric CML
Frédéric Millot,
CHU de Poitiers, France

  • Clinical and biological characteristics of childhood CML
  • Tyrosine kinase inhibitors in children and adolescents
  • Treatment discontinuation in children with CML in chronic phase

14:20-14:45

Altered Metabolism of Hematooietic Cells in Myeloproliferative Neoplasms as a Potential Therapeutic Target
Radek Skoda, University Hospital Basel, 
Switzerland

14:45-15:00

Discussion 

15:00-15:30

Coffee Break, Poster Viewing and Exhibition

15:30-16:30

Session 4: Chronic Lymphocytic Leukemia – A Personalized Approach Towards Cure
Chairperson: Jan Burger, The University of Texas MD Anderson Cancer Center, USA

15:30-15:55

Novel Targeted Drugs for Relapsed/Refractory Chronic Lymphocytic Leukemia
Tadeusz Robak, Medical University of Lodz, Poland

15:55-16:20

The History of CLL Research
Uri Rozovski,
Rabin Medical Center, Israel

  • Differential use of DNA-repair mechanisms may explain why compared with mutated IGHV, unmutated IGHV CLLs have adverse prognosis.
  • A fraction of patients with mutated IGHV status are cured with FCR. Patients with Low levels of beta2 mircroglobulin, and those who achieve minimal residual disease (MRD) negativity are more likely go get cured.
  • Because at least 3 distinct signaling pathways are constitutively active in CLL, therapeutic agents that target only one of these pathways have failed in the clinics. 

16:20-16:30

Discussion


Friday, 5 April 2019

08:30-16:30

Registration

09:00-10:30

Session 5: Interdisciplinary Perspectives – An Obligatory Need for Cure
Chairperson: Ran Kornowski, Rabin Medical Center, Israel

09:00-09:25

Managing Antithrombotic Therapy During Thrombocytopenia in Leukemia: From Aspirin to DOACs
Avi Leader, Rabin Medical Center, Israel

  • Understand the short-term risk of thrombosis in leukemia patients with an indication for antithrombotic medication
    • Indications covered include atrial fibrillation, venous thromboembolism and ischemic heart disease
  • Describe the bleeding risk associated with various types of antithrombotic therapy in thrombocytopenic leukemia patients
  • Select appropriate management of the antithrombotic medication prescribed for these various indications

09:25-09:50

Towards Hemostatic Profiling in the Individual Patient: Fiction or Reality?
Hugo ten Cate, Maastricht University, 
The Netherlands

  • It remains difficult to estimate risks of thromboembolism (TE) in individual patients and this is a significant clinical problem; laboratory testing has not yet provided a solution.
  • Various factors may explain this lack of diagnostic tools: dogmatic views on hemostasis and thrombosis (testing) pose a hurdle to development of better suited tests
  • The future should provide test based individual patient “signatures” that predict with greater certainty risk of TE (or bleeding), but also the optimal type and level of antithrombotic therapy.

09:50-10:15

Cardiovascular Aspects of Leukemia Management
Ran Kornowski, 
Rabin Medical Center, 
Israel

10:15-10:30

Discussion 

10:30-11:00

Coffee Break, Poster Viewing and Exhibition

11:00-11:20

Sponsored Symposia: Beckman Coulter Life Sciences

Innovative Solutions for Rare Event Detection in B-ALL
Dr. Michael Dworzak,
 St. Anna Kinderkrebsforschung e.V., Immundiagnostik, Austria

11:20-12:00

Oral Presentations
Chairperson: Pia Raanani, Israel

 
11:20-11:30

Questionable Pediatric Studies in Acute Lymphoblastic Leukemia (ALL)
Klaus Rose,
Switzerland
 
11:30-11:40


Use of Intravenous Pamidronate in Pediatric Acute Lymphoblastic Leukemia Patients with Osteonecrosis (ON) Results in Reduced Pain and Improved Radiologic outcome of ON lesions
Paivi Miettunen, Ronald Anderson, Tony Truong, Seemab Haider, Vijay Moorjani, Seamus Stephenson, Chloe Stephenson, Canada


11:40-11:50


92R Monoclonal Antibody Displays Excellent Therapeutic Possibilities for The Treatment of Human CCR9+-T Cell Acute Lymphoblastic Leukemia

Silvia Santamaría, Marisa Delgado, Jose A. Garcia-Sanz, Mercedes Llorente, Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, María Vela, Leonor Kremer, Spain


11:50-12:00
 

Identification of an Adherent Cell that Interact with Leukemic Cells and Induced Chemo Resistance
Massoud Mirshahi,
France


12:00-12:15
 

A computational method for the assessment of bone and bone marrow alteration and metabolism using whole body PET/CT data
Michele Piana
, Gianmario Sambuceti, Cristina Campi, Francesco Fiz, Cecilia Marini, Anna Maria Massone, Francesco Frassoni, Italy

 
12:15-12:30


Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) In Patients with Chronic Lymphocytic Leukemia (CLL)
Jan A. Burger
, Mariela Sivina, Alessandra Ferrajoli, Nitin Jain, Ekaterina Kim, Tapan Kadia, Zeev Estrov, Graciela M Nogueras-Gonzalez, Xuelin Huang, Maro Ohanian, Michael Andreeff, Mathew Thomas, Hagop Kantarjian, Susan O’Brien, William G. Wierda, Michael J. Keating, USA

12:30-13:30

Lunch Break, Poster Viewing and Exhibition

13:30-15:00

Session 7: Acute Leukemia in 2019– Will Targeted Therapy Suffice for Cure?
Chairperson: William H. Krüger, Greifswald-University, Germany

13:30-13:55

From Hybrid to Mixed Phenotype Acute Leukemia: Emerging Approaches to Target Rare Leukemias
Ofir Wolach,
Rabin Medical Center, Israel

  • Diagnostic systems for MPAL
  • Therapeutic approaches for MPAL
  • The genetic landscape and potential targeted approaches for MPAL

13:55-14:20

Allogeneic Stem Cell Transplantation for AML – Which Patients Benefit?
William H. Krüger, Greifswald-University, Germany

  • Allogeneic stem cell transplantation can cure AML with an otherwise infaust prognosis
  • AlloSCT is associated with a considerable morbidity and mortality
  • Outcome after alloSCT depends from disease-related, patient-related and donor-related issues

14:20-14:45

CAR T Cells for Leukemia – Where We Stand and Where We’re Heading
Elad Jacoby, Sheba Medical Center, Israel

  • Current clinical results of CAR T cells for acute lymphoblastic leukemia
  • Resistance mechanisms to CAR T cells
  • Future design of CAR T cells

14:45-15:00

Discussion

15:00-15:30

Coffee Break, Poster Viewing and Exhibition 

15:30-16:55

Session 8: Chronic Myeloid Leukemia and Cure – Are We Already There?
Chairperson: Jane Apperley, Imperial College London, UK

15:30-15:55


Choosing First Line Therapy to Optimise Patient Care
Jane Apperley,
Imperial College London, 
UK
  • To understand the relative outcomes of treatment with the four tyrosine kinase inhibitors currently available for firstline treatment in chronic myeloid leukemia
  • To appreciate the patient related factors that can drive the choice of firstline therapy in chronic myeloid leukemia
  • To appreciate the drug related factors that can drive the choice of firstline therapy in chronic myeloid leukemia

15:55-16:20

NGS-based BCR-ABL1 Mutation Screening in Patients with Failure and Warning Responses
Simona Soverini,
University of Bologna, Italy

  • Acquisition of drug resistant BCR-ABL1 mutations may undermine the efficacy of TKI therapy; mutations are not the only mechanism of drug resistance we know of, yet they are the only actionable one
  • Preventing the clonal expansion of TKI-resistant mutants rather than counteracting already grown mutant clones is essential to improve the outcome of therapy
  • NGS has been proven to be a robust tool for sensitive identification of emerging mutations

16:20-16:45

Optimal Condidates to Try Treatment Discontinuation (TFR) in CML
Giuseppe Saglio, University of Turin, Italy

  • Treatment discontinuation (TFR) is becoming a real option for CML patients in deep molecular response.
  • Criteria associated with a major possibility of remaining in TFR
  • Future challenges in CML

16:45-16:55

Discussion

16:55-17:00

Congress Closing and Best Abstract Award
Pia Raanani, Israel